Tag: Pharmaceutical

sanofi
Europe

Opella reaches study milestone for Cialis

Press Release – Paris, January 21, 2025. Opella, Sanofi’s Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on its planned actual use trial (AUT) to support the switch of Cialis (tadalafil) from a prescription to an over-the-counter medicine. This decision allows for the initiation of the AUT and makes Cialis the first PDE-5 inhibitor to achieve … Continue reading Opella reaches study milestone for Cialis

Impact Newswire
servier
Europe

Servier appoints David K. Lee to Executive Committee

Press Release – 13 January 2025 – Suresnes (France), January 13th, 2025 – Servier, an independent international pharmaceutical group, announces the appointment of David K. Lee to its Executive Committee as Executive Vice President for the United States, effective January 1, 2025. David K. Lee has held the position of Chief Executive Officer (CEO) of Servier Pharmaceuticals in the United States since the creation of … Continue reading Servier appoints David K. Lee to Executive Committee

Impact Newswire
hovione
Europe

Hovione strengthens its global position as a top employer for the third consecutive year

Hovione has once again solidified its position as a top employer. Press Release – Jan 16, 2025 Lisbon, January 16, 2025 – Hovione, an international integrated pharmaceutical development and manufacturing organization, has once again solidified its position as a top employer. For the third consecutive year, all four of its manufacturing sites – Lisbon (Portugal), Cork (Ireland), East Windsor (NJ, USA), and Macau – have been … Continue reading Hovione strengthens its global position as a top employer for the third consecutive year

Impact Newswire
IDRx
Untied Kingdom

GSK Enters Agreement to Acquire IDRx, Inc.

Press Release – January 13, 2025 – PLYMOUTH, Mass. – GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST. Under the agreement, GSK will pay $1 billion upfront, with potential for an additional $150 million success-based … Continue reading GSK Enters Agreement to Acquire IDRx, Inc.

Impact Newswire
JOHNSON & JOHNSON
United States

Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for CAPLYTA® as adjunctive treatment for major depressive disorder; if approved, CAPLYTA® has potential to become a standard of care for most common depressive disorders CAPLYTA® adds to Johnson & Johnson’s robust lineup of … Continue reading Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.

Impact Newswire